Evidence map›Paper›PMID 41598768›Full record

ReviewJournal of clinical medicine2026

Optimizing Lymph Node Staging in Non-Small Cell Lung Cancer Surgery: Evidence, Guidelines, and Quality Improvement Strategies.

Dimitrios E Magouliotis, Vasiliki Androutsopoulou, Ugo Cioffi, Fabrizio Minervini, Noah Sicouri, Andrew Xanthopoulos, Marco Scarci

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dimitrios E MagouliotisDepartment of Cardiac Surgery Research, Lankenau Institute for Medical Research, Wynnewood, PA 19096, USA.ORCID 0000-0001-5417-6392
Vasiliki AndroutsopoulouDepartment of Cardiothoracic Surgery, University of Thessaly, Biopolis, 41110 Larissa, Greece.ORCID 0009-0005-2445-0879
Ugo CioffiDepartment of Surgery, University of Milan, 20157 Milan, Italy.ORCID 0000-0002-5321-5828
Fabrizio MinerviniDepartment of Thoracic Surgery, Luzern Kanton Hospital, 6000 Luzern, Switzerland.
Noah SicouriDepartment of Neuroscience Pittsburgh Campus, University of Pittsburgh, Pittsburgh, PA 15260, USA.
Andrew XanthopoulosDepartment of Cardiology, University of Thessaly, Biopolis, 41110 Larissa, Greece.ORCID 0000-0002-9439-3946
Marco ScarciDepartment of Cardiothoracic Surgery, Hammersmith Hospital, Imperial College Healthcare, National Health Service (NHS) Trust, London W2 1NY, UK.ORCID 0000-0002-4459-7721

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lymph node evaluation is a central determinant of oncologic quality in the surgical management of non-small-cell lung cancer (NSCLC). Accurate assessment of hilar and mediastinal lymph nodes underpins pathologic staging, informs postoperative treatment decisions, and remains essential for prognostic stratification and assessment of resection completeness. Although international guidelines provide clear recommendations, real-world data consistently demonstrate substantial variability in lymph node staging practices, with inadequate evaluation frequently observed across institutions and surgical settings. Insufficient nodal assessment, manifested as the omission of mediastinal staging, limited station sampling, or low lymph node yield, is associated with reduced nodal upstaging, inappropriate omission of adjuvant therapy, higher recurrence rates, and inferior long-term survival. Contemporary guidance from major societies, including the National Comprehensive Cancer Network, European Society of Thoracic Surgeons, International Association for the Study of Lung Cancer, and the Commission on Cancer, has increasingly converged on a station-based definition of adequacy, emphasizing systematic evaluation of both N1 and N2 nodal stations rather than reliance on absolute node counts alone. In parallel, preoperative mediastinal staging algorithms have evolved toward routine use of endobronchial and esophageal ultrasound as first-line invasive modalities, reserving surgical mediastinoscopy for selected high-risk or inconclusive cases. Evidence from randomized trials, population-level databases, and meta-analyses indicates that thorough nodal assessment improves staging accuracy and survival, while recent data support the selective use of lobe-specific or tailored lymphadenectomy in carefully staged, low-risk early disease. Finally, emerging quality improvement interventions, including standardized specimen handling, operative checklists, and multidisciplinary feedback mechanisms, have demonstrated measurable improvements in guideline adherence and patient outcomes. This narrative review integrates contemporary evidence and guideline recommendations to outline a practical framework for implementing reliable, high-quality lymph node staging in modern lung cancer surgery.

Indexed as

lung cancerlymph node stagingmediastinal lymphadenectomynon-small-cell lung cancer (NSCLC)quality improvementsurgery

Identifiers

PMID41598768
PMCPMC12842253

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.